Grifols
GRFS
7.50
-0.02
-0.27%
Grifols
US · GRFS
#2138 by market cap
Listed 1970
7.50
-0.02
-0.27%
Live - 5344 symbols - heartbeat 202s ago
· 2026-10-08 08:17
Pre-market
7.40
-1.33%
After-hours
7.50
0.00%
- Market cap
- 5.10B
- P/E (TTM)i
- 10.15
- P/Bi
- 0.82
- EPSi
- 0.66
- Div yieldi
- 3.71%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on GRFS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.05, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +4.33% YoY
Margins
- Gross margin
- 38.00%
- Operating margin
- 16.63%
- Net margin
- 5.34%
Key ratios & quality
- Enterprise valuei
- 12.88B
- PEG ratioi
- 0.34
- Altman Z-Scorei
- 1.05
PEG uses trailing P/E against the 3-year net income growth rate (29.52%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.49B | 5.10B | 5.34B | 4.93B | 6.06B | 6.59B | 7.21B | 7.52B |
| Gross profit | 2.05B | 2.34B | 2.26B | 1.96B | 2.21B | 2.48B | 2.79B | 2.86B |
| Selling & admin expenses | 814.78M | 942.82M | 985.62M | 1.06B | 1.11B | 1.27B | 1.14B | 1.06B |
| Research & development | 240.66M | 276.02M | 294.22M | 354.88M | 361.14M | 395.00M | 384.00M | 426.00M |
| Operating profit | 994.12M | 1.12B | 975.33M | 562.51M | 678.96M | 718.00M | 1.16B | 1.25B |
| Pretax profit | 725.84M | 817.10M | 878.63M | 350.45M | 338.01M | 206.00M | 444.00M | 615.00M |
| Tax | 131.44M | 168.46M | 169.64M | 85.13M | 90.11M | 43.00M | 231.00M | 115.00M |
| Net profit | 594.41M | 648.64M | 708.99M | 265.33M | 247.90M | 163.00M | 213.00M | 500.00M |
| Basic EPS | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Diluted EPS | 0.87 | 0.91 | 0.90 | 0.28 | 0.27 | 0.06 | 0.23 | 0.59 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.79B | 1.89B | 1.87B | 1.98B | 1.70B | 1.87B |
| Gross profit | 695.00M | 744.00M | 733.70M | 686.84M | 620.00M | 705.00M |
| Selling & admin expenses | 325.00M | 298.00M | 284.99M | 155.30M | 281.00M | 289.00M |
| Research & development | 96.00M | 96.00M | 97.02M | 136.74M | 90.00M | 87.00M |
| Operating profit | 274.00M | 350.00M | 352.11M | 275.38M | 249.00M | 329.00M |
| Pretax profit | 115.00M | 191.00M | 198.13M | 111.10M | 112.00M | 247.00M |
| Tax | 23.00M | 52.00M | 54.71M | -14.68M | 24.00M | 64.00M |
| Net profit | 92.00M | 138.00M | 143.43M | 125.77M | 88.00M | 183.00M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.09 | 0.17 | 0.19 | 0.14 | 0.11 | 0.23 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 3.48B | 5.36B | 3.16B | 5.51B | 4.69B | 6.13B | 5.73B | 5.07B |
| Cash & ST investments | 1.09B | 2.47B | 590.51M | 2.68B | 580.24M | 544.50M | 1.00B | 824.00M |
| Inventory | 1.95B | 2.34B | 2.00B | 2.26B | 3.24B | 3.48B | 3.56B | 3.30B |
| Total assets | 12.48B | 15.54B | 15.27B | 19.23B | 21.23B | 20.99B | 21.41B | 19.71B |
| Total current liabilities | 1.26B | 1.37B | 1.34B | 3.47B | 2.02B | 2.33B | 2.16B | 2.02B |
| Short-term debt | 7.08M | 320.80M | 319.57M | 2.39B | -- | 987.91M | 668.00M | 523.00M |
| Long-term debt | -- | 6.09B | 5.90B | 6.10B | -- | 8.98B | 8.42B | 8.07B |
| Total liabilities | 7,780,442,000.00 | 8,696,843,000.00 | 8,554,721,000.00 | 11,916,737,000.00 | 13,253,455,000.00 | 13,478,408,000.00 | 12,799,000,000.00 | 12,109,000,000.00 |
| Total equity | 4.70B | 6.85B | 6.72B | 7.32B | 7.98B | 7.51B | 8.61B | 7.60B |
| Retained earnings | 459.90M | 488.32M | 618.55M | 188.73M | 0 | 42.32M | 157.00M | 300.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 5.25B | 5.35B | 5.07B | 5.25B | 5.31B |
| Cash & ST investments | -- | 565.80M | 825.48M | 824.00M | 758.00M | 529.00M |
| Inventory | -- | 3.35B | 3.35B | 3.30B | 3.46B | 3.49B |
| Total assets | -- | 19.77B | 19.85B | 19.71B | 20.08B | 20.09B |
| Total current liabilities | -- | 1.99B | 2.15B | 2.02B | 2.12B | 2.24B |
| Short-term debt | -- | 393.97M | -- | 523.00M | 589.00M | 420.00M |
| Long-term debt | -- | 7.45B | -- | 8.07B | -- | 7.17B |
| Total liabilities | -- | 12,169,006,000.00 | 12,305,806,000.00 | 12,109,000,000.00 | 12,231,000,000.00 | 12,110,000,000.00 |
| Total equity | -- | 7.60B | 7.55B | 7.60B | 7.85B | 7.98B |
| Retained earnings | -- | 176.79M | 303.75M | 300.00M | 73.00M | 227.00M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 737.43M | 568.93M | 1.11B | 596.98M | -1.43M | 217.00M | 902.00M | 1.05B |
| Depreciation & amortization | 228.61M | 302.46M | 321.53M | 359.77M | 410.98M | 446.00M | 438.00M | 450.00M |
| Free cash flow | 429.71M | 156.63M | 747.78M | 281.89M | -394.30M | -93.00M | 530.00M | 624.00M |
| Dividends paid | -278.84M | -238.74M | -113.23M | -258.95M | -592.00K | 0 | -1.00M | -128.00M |
| Stock buybacks / issuance | -- | 0 | 0 | -125.70M | -3.46M | -- | -- | -- |
| Ending cash balance | 1.03B | 741.98M | 579.65M | 2.68B | 549.21M | 529.00M | 980.00M | 825.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 136.00M | 157.00M | 325.40M | 430.86M | 110.00M | 227.00M |
| Depreciation & amortization | 112.00M | 107.00M | 102.85M | 128.37M | 104.00M | 107.00M |
| Free cash flow | 48.00M | 63.00M | 218.82M | 296.72M | 20.00M | 108.00M |
| Dividends paid | -- | -- | -102.38M | -25.62M | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | -- | -- | -- |
| Ending cash balance | 753.00M | 561.00M | 620.96M | 825.00M | 702.00M | 513.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 15.19 | 13.82 | 12.46 | 3.55 | 3.57 | 0.99 | 2.68 | 7.21 |
| ROA %i | 5.10 | 4.46 | 4.01 | 1.09 | 1.02 | 0.28 | 0.73 | 1.96 |
| ROIC %i | 8.04 | 7.06 | 6.61 | 2.66 | 2.96 | 2.67 | 3.61 | 5.47 |
| 5-year avg ROE %i | 17.28 | 16.09 | 15.01 | 12.61 | 9.67 | 6.78 | 4.57 | 3.52 |
| EBIT margin %i | 22.29 | 22.39 | 20.63 | 11.84 | 11.94 | 11.23 | 14.51 | 15.83 |
| FCF / sales %i | 9.58 | 3.07 | 14.00 | 5.71 | -- | -- | 7.36 | 8.29 |
| Current ratioi | 2.77 | 3.92 | 2.37 | 1.59 | 2.32 | 2.64 | 2.66 | 2.51 |
| Quick ratioi | 1.19 | 2.15 | 0.82 | 0.91 | 0.67 | 0.63 | 0.96 | 0.83 |
| Debt / assetsi | 0.06 | 45.73 | 45.25 | 48.48 | -- | 52.27 | 47.25 | 48.53 |
| LT debt / equityi | -- | 140.73 | 129.04 | 125.46 | -- | 186.00 | 160.55 | 171.56 |
| Interest coveragei | 3.65 | 3.52 | 4.94 | 2.50 | 2.00 | 1.43 | 1.74 | 2.07 |
| Revenue CAGR (3Y) %i | 4.47 | 7.98 | 7.34 | 3.21 | 5.95 | 7.27 | 13.50 | 7.46 |
| Net income CAGR (3Y) %i | 3.89 | 4.65 | -2.27 | -31.86 | -33.36 | -59.20 | -5.95 | 29.52 |
| FCF CAGR (3Y) %i | 34.72 | -15.61 | 12.96 | -13.11 | -- | -- | 23.42 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | 5.53 | 7.08 | 7.21 | 7.60 | 8.44 |
| ROA %i | -- | 1.41 | 1.86 | 1.96 | 2.07 | 2.27 |
| ROIC %i | -- | 4.06 | 12.97 | 5.47 | 2.74 | 5.94 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | 15.86 | 15.94 | 15.83 | 15.68 | 17.15 |
| FCF / sales %i | -- | 9.34 | 9.30 | 8.29 | 8.01 | 8.64 |
| Current ratioi | -- | 2.64 | 2.48 | 2.51 | 2.47 | 2.37 |
| Quick ratioi | -- | 0.91 | 0.89 | 0.83 | 0.81 | 0.77 |
| Debt / assetsi | -- | 44.62 | -- | 48.53 | 48.16 | 42.39 |
| LT debt / equityi | -- | 163.00 | -- | 171.56 | 166.36 | 146.00 |
| Interest coveragei | -- | 2.17 | 2.48 | 2.07 | -- | 2.10 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- BioPharma is the largest reported line at 86.22% of revenue, across 4 reported segments.
- The next-largest line, Diagnostic, is a distant second at 8.51% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
BioPharma86.22%
Diagnostic8.51%
Others3.23%
Bio Supplies2.05%
Region
USA and Canada56.53%
Rest of the World22.02%
Rest of European Union15.90%
Spain5.56%
Quote time 2026-10-08 08:17:15 · For reference only, not investment advice and not tailored to your situation.